NFKB1 and lymphoma: The knowledge about how a certain oncogenic lesion drives NF-κB activation as well as the identification and molecular characterization of novel oncogenic mechanisms governing lymphomagenesis will pave the way for the rational design of therapeutic strategies, for instance by simultaneously targeting complementary signaling pathways, and thus improve lymphoma therapy.